The purpose of the proposed research is to determine how plasma lipoproteins and apolipoproteins bound to lymphocyte membrane receptors - termed proliferation-restraint receptors - inhibit mitogenic recruitment of the cells into and passage through the cell cycle, thereby inhibiting mitogen-induced cell proliferation. The suppressor molecules inhibit biochemical process -e.g., enhanced metabolism of phosphatidylinositol (PI) - which occur within the first hours post-stimulation. Inhibition correlates directly with extent of receptor occupancy. The hypothesis to be tested is that PI metabolism is important in the production of growth factors and/or growth factor receptors which are required for the activated cells to undergo mitosis. The hypothesis will be tested in systems containing defined cellular phenotypes and relying on assays in which events can be assessed in idividual cells by flow cytometry. The three specific aims are: (1) to determine the phenotype of the lymphoid cells required to generate the PI response and to modulate suppression of this response by AP/LP, (2) to determine the influence of AP/LP on IL-2 receptor expression and IL-2 production, paying particular attention to the relationship between the PI response, IL-2 receptor expression and IL-2 production, and (3) To characterize the proliferation-restraint receptor by its specificity for well-characterized ligands and its sensitivity to modification-inactivation. The long term goals of the research are (1) to determine the structure of the lymphocyte proliferation-restraint receptor which recognizes apolipoproteins; (2) to elucidate the mechanism by which it functions to restrict lymphocyte proliferation at the molecular level; (3) to identify the cells, lymphocyte and nonlymphocyte, which express it and are therefore sensitive to its function; and (4) to understand the factors which regulate its expression and its activity. Lipoproteins are natural modulators of the functional capacity of the immune system. Suppression of immune responsiveness by lipoproteins is important in diseases such as cancer in which host immune competence may be a primary defense mechanism. In cell biology/physiology, the proliferation-restraint receptor offers the opportunity to define recruitment of lymphocytes from the nonproliferating state in molecular terms.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Cincinnati
Schools of Medicine
United States
Zip Code
Forte, T M; Oda, M N; Knoff, L et al. (1999) Targeted disruption of the murine lecithin:cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration. J Lipid Res 40:1276-83
Tolar, M; Marques, M A; Harmony, J A et al. (1997) Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. J Neurosci 17:5678-86
Marques, M A; Tolar, M; Harmony, J A et al. (1996) A thrombin cleavage fragment of apolipoprotein E exhibits isoform-specific neurotoxicity. Neuroreport 7:2529-32
Dumaswala, R; Brown, T L (1996) Sulphydryl modification inhibits taurine transport in human placental brush border membranes. Placenta 17:329-36
Mistry, M J; Clay, M A; Kelly, M E et al. (1995) Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Cell Immunol 160:14-23
Clay, M A; Anantharamaiah, G M; Mistry, M J et al. (1995) Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry 34:11142-51
Kelly, M E; Clay, M A; Mistry, M J et al. (1994) Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell Immunol 159:124-39
Crutcher, K A; Clay, M A; Scott, S A et al. (1994) Neurite degeneration elicited by apolipoprotein E peptides. Exp Neurol 130:120-6
Witte, D P; Aronow, B J; Stauderman, M L et al. (1993) Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol 143:763-73
Lilly-Stauderman, M; Brown, T L; Balasubramaniam, A et al. (1993) Heparin releases newly synthesized cell surface-associated apolipoprotein E from HepG2 cells. J Lipid Res 34:190-200

Showing the most recent 10 out of 27 publications